# A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

> **NCT06132126** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 66 (actual)

## Conditions studied

- Healthy
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LY3938577
- **DRUG:** Placebo
- **DRUG:** Insulin degludec

## Key facts

- **NCT ID:** NCT06132126
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-17
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132126, "A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06132126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*